Anthem Blue Cross

Prior authorization requirements for Part B Injectable/infusible drugs: Aliqopa (copanlisib injection), Cinvanti (aprepitant injection) and Opsiria (sirolimus injection)

On March 1, 2018, Anthem Blue Cross prior authorization (PA) requirements will change for three (3) Part B Injectable/Infusible drugs: Aliqopa (copanlisib injection), Cinvanti (aprepitant injection) and Opsiria (sirolimus injection). Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these prior authorization rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

PA requirements will be added to the following codes which are Part B drugs billed with Not Otherwise Classified (NOC) HCPCS J codes [J3490, J3590, J9999]; unlisted, because no J Code has been established at this time:

- Aliqopa (copanlisib injection): for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments. [J9999]

- Cinvanti (aprepitant injection): for the treatment of chemotherapy-induced nausea and vomiting. [J3490, J3590]

- Opsiria (sirolimus injection): for the treatment uveitis and works by blocking an enzyme called “mammalian target of rapamycin” (mTOR). [J3490, J3590]

Since these codes include all drugs that are NOC, if the authorization is denied for medical necessity, the plan’s denial will be for the drug and not the HCPCS.

Not all prior authorization requirements are listed here. Detailed prior authorization requirements are available to contracted providers by accessing the “Provider Self-Service Tool” within Availity. Non-contracted providers should contact the Health Plan.

Anthem Blue Cross is the trade name of Blue Cross of California: Independent licensee of the Blue Cross Association. ® ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.